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A B S T R A C T
Hypochlorous acid added as reagent or generated by the myeloperoxidase (MPO)-H2O2-Cl
 system
oxidatively modiﬁes brain ether-phospholipids (plasmalogens). This reaction generates a sn2-acyl-
lysophospholipid and chlorinated fatty aldehydes. 2-Chlorohexadecanal (2-ClHDA), a prototypic
member of chlorinated long-chain fatty aldehydes, has potent neurotoxic potential by inﬂicting blood–
brain barrier (BBB) damage. During earlier studies we could show that the dihydrochalcone-type
polyphenol phloretin attenuated 2-ClHDA-induced BBB dysfunction. To clarify the underlying
mechanism(s) we now investigated the possibility of covalent adduct formation between 2-ClHDA
and phloretin. Coincubation of 2-ClHDA and phloretin in phosphatidylcholine liposomes revealed a half-
life of 2-ClHDA of approx. 120 min, decaying at a rate of 5.9  103 min1. NMR studies and enthalpy
calculations suggested that 2-ClHDA-phloretin adduct formation occurs via electrophilic aromatic
substitution followed by hemiacetal formation on the A-ring of phloretin. Adduct characterization by
high-resolution mass spectroscopy conﬁrmed these results. In contrast to 2-ClHDA, the covalent
2-ClHDA-phloretin adduct was without adverse effects on MTT reduction (an indicator for metabolic
activity), cellular adenine nucleotide content, and barrier function of brain microvascular endothelial
cells (BMVEC). Of note, 2-ClHDA-phloretin adduct formation was also observed in BMVEC cultures.
Intraperitoneal application and subsequent GC–MS analysis of brain lipid extracts revealed that
phloretin is able to penetrate the BBB of C57BL/6J mice. Data of the present study indicate that phloretin
scavenges 2-ClHDA, thereby attenuating 2-ClHDA-mediated brain endothelial cell dysfunction. We here
identify a detoxiﬁcation pathway for a prototypic chlorinated fatty aldehyde (generated via the MPO
axis) that compromises BBB function in vitro and in vivo.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The neurovascular unit physically separates most regions of
the brain from the periphery to maintain central nervous
system homeostasis [1]. Within this specialized vessel system,
brain microvascular endothelial cells (BMVEC) constitute the
morphological basis of the blood–brain barrier (BBB) [2]. The* Corresponding author.
E-mail address: wolfgang.sattler@medunigraz.at (W. Sattler).
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http://dx.doi.org/10.1016/j.bcp.2014.12.017
0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articformation of tight junctions prevents paracellular transport of
molecules and cells and maintains homeostasis of the brain
micromilieu via elaborately regulated transport mechanisms.
Under inﬂammatory conditions BBB function is compromised
and can aggravate neuronal dysfunction [3]. Many pathways that
compromise BBB and neuronal function in further consequence
have been shown to converge on the formation of reactive species
[4]. This is of particular importance since tight junction proteins
are sensitive to alterations of the intracellular redox status,
ultimately resulting in barrier dysfunction [5]. Various effects of
reactive oxygen species e.g. inhibition of cerebral blood ﬂow and
alterations in barrier integrity have been demonstrated inle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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stroke causes an increase in cell volume, depolarization, break-
down of ionic gradients, cellular ATP depletion, and ﬁnally
vasogenic edema in response to BBB breakdown [8].
During our earlier studies we could show pronounced BMVEC
barrier dysfunction in response to the fatty aldehyde 2-chlorohex-
adecanal (2-ClHDA) that is generated during endotoxemia [9,10]. 2-
ClHDA is formed by attack of plasmalogens (ether phospholipids) by
hypochlorous acid (HOCl) [11,12]. HOCl in turn is generated by the
myeloperoxidase (MPO)–H2O2–Cl
 system of activated phagocytes
[13], cells that release MPO at the cerebrovasculature [10]. Under
physiological conditions MPO is part of the innate immune system,
however, under chronic inﬂammatory conditions the MPO–H2O2–
Cl system is implicated in the development of (neurological)
diseases. MPO is abundantly expressed in microglia in and around
demyelinated lesions in Multiple Sclerosis in humans and rodents
[14]. In line, pharmacological inhibition of MPO reduced the severity
of clinical symptoms in a murine model of Multiple Sclerosis [15].
The involvement of MPO in barrier dysfunction was also demon-
strated during bacterial meningitis [16,17]. We recently reported
signiﬁcantly elevated MPO levels in mouse brain in response
to systemic lipopolysaccharide (LPS) administration [9]. MPO
expression was accompanied by a signiﬁcant decrease of brain
plasmalogen content and concomitant formation of 2-ClHDA [9]. In
line with deleterious effects of MPO-generated 2-ClHDA we could
show that LPS-induced BBB dysfunction was signiﬁcantly less
pronounced in MPO/ mice as compared to the corresponding
littermates [10].
Zhu and colleagues [18] suggested that chemical trapping of
reactive aldehydes by polyphenols could provide an attractive
approach to prevent cellular dysfunction in response to Schiff’s
base formation between vital cellular proteins and reactive
aldehydes. We recently reported that phloretin, a dihydrochal-
cone-type polyphenol, prevented 2-ClHDA-induced barrier dys-
function, apoptosis, and ATP depletion in BMVEC in vitro by yet
unidentiﬁed mechanisms [19]. To reveal the underlying mecha-
nisms of adduct formation between 2-ClHDA and phloretin we
applied NMR analysis, theoretical enthalpy calculations, and high-
resolution mass spectroscopy (HRMS). To get an indication about
altered toxicity proﬁles after adduct formation, metabolic activity,
the cellular adenine nucleotide status, and barrier function was
studied in BMVEC. To obtain ﬁrst evidence about BBB permeability
of phloretin in vivo, uptake of i.p. injected phloretin was
quantitated in murine brain.
2. Materials and methods
Cell culture supplies were from Gibco (Vienna, Austria), PAA
Laboratories (Linz, Austria), Costar (Vienna), or VWR (Vienna).
Dulbecco’s modiﬁed Eagle’s medium (DMEM) Ham’s F12, hydrocor-
tisone, N-chlorosuccinimide, DL-proline, dipalmitoylphosphati-
dylcholine (DPPC), phloretin (3-(4-hydroxyphenyl)-1-(2,4,6-
trihydroxyphenyl) propan-1-on), resveratrol, pentaﬂuorobenzyl
(PFB) hydroxylamine, dimethyl sulfoxide (DMSO), and 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT)
were from Sigma-Aldrich (Vienna). Electrical cell-substrate
impedance sensing (ECIS) electrode arrays (8W10E+) were from
Ibidi (Martinsried, Germany). Hexadecanal was from Toronto
Research Chemicals (Toronto, Canada). N-Methyl-N-(trimethylsi-
lyl)-triﬂuoroacetamide (MSTFA) was from ABCR (Karlsruhe,
Germany), trimethylchlorosilane (TMCS) and pyridine were from
Pierce (Rockford, IL, USA). Silica 60 gel and silica 60 TLC plates were
from Merck (Darmstadt, Germany). Poly-Prep1 chromatography
columns were from Bio-Rad (Vienna). Phosphospeciﬁc rabbit
polyclonal anti-pp44/42 MAPK (Thr202/Tyr204), anti-pSAPK/JNK1/2
(Thr183/Tyr185), pan-speciﬁc rabbit monoclonal anti-p44/42, andrabbit polyclonal anti-SAPK/JNK1/2 antibodies were from Cell
Signaling Technology (Beverly, MA). HRP-labeled secondary
goat anti-rabbit IgG was from Pierce (Rockford, IL). All solvents
and other reagents of analytical grade were from Merck, Sigma-
Aldrich, or Roth.
2.1. Synthesis of 2-chlorohexadecanal (2-ClHDA)
2-ClHDA was synthesized by organocatalytic a-chlorination of
hexadecanal [20]. DL-Proline (0.2 equ.) followed by N-chlorosucci-
nimide (1.5 equ.) were added to a solution of hexadecanal (1 equ.)
in 4 ml CH2Cl2 at 0 8C. The suspension was allowed to warm to
ambient temperature and was stirred over night. Hexane
(15 ml) was added to the reaction mixture and the precipitate
was ﬁltered. 2-ClHDA was puriﬁed using a Silica 60 column
and hexane/diethyl ether (90:10, v/v) as eluent (yield = 51%).
2-Cl[13C8]HDA used as internal standard for gas chromatography–
mass spectroscopy (GC–MS) analysis was synthesized and puriﬁed
as described [9].
2.2. Analytical procedures
DPPC liposomes containing equimolar concentrations of
phloretin and 2-ClHDA were prepared by dispersing a mixture
of 2.5 mg DPPC (0.7 mM), 350 mg phloretin (0.3 mM), and 350 mg
2-ClHDA (0.3 mM) in 2 ml phosphate-buffered saline (PBS, pH 7.4).
The mixture was sonicated on ice for 3  10 s. The reaction was
started by gently stirring the mixture at 37 8C in the dark under
an argon atmosphere. At the indicated time points 100 ml
aliquots (approx. 18 nmol of reactants) were removed and
250 ng 2-Cl[13C8]HDA [9] was added. Samples were immediately
extracted twice with ethyl acetate (2 ml) followed by a Folch
extraction. Extracts were stored at 70 8C until analysis. After
conversion to the corresponding PFB-oxime derivatives 2-ClHDA
was quantitated by negative ion chemical ionization (NICI)–GC–
MS. Alternatively adduct formation was studied in acetonitrile,
tetrahydrofurane (THF; both solvents containing 1% triethylamine;
240 mM 2-ClHDA and phloretin), or high-density lipoproteins
(HDL; 80 mM 2-ClHDA and phloretin in PBS containing 250 mg HDL
protein/ml). HDL was isolated from plasma as described [21].
Following extraction, phloretin and adduct concentrations were
quantitated by HPLC (see below). A one-phase exponential decay
model (Ct = C0  ekt) was used to ﬁt experimental data using the
Prism 5.0 software (GraphPad, San Diego, CA, USA).
2.3. Derivatization for GC–MS
Preparation of PFB-oxime derivatives of 2-ClHDA and 2-
Cl[13C8]HDA for NICI–GC–MS was performed as described above.
Phloretin and resveratrol were converted to the corresponding
trimethylsilyl (TMS)-ether derivatives in 100 ml MSTFA/pyridine
(2:1; v/v) containing 1% (v/v) TMCS at room temperature (RT) for
30 min immediately before electron impact (EI)–GC–MS analysis
due to putative phloretin keto-enol tautomerism.
2.4. NICI–GC–MS and EI–GC–MS
Samples were separated on a Thermo Scientiﬁc Trace GC Ultra
(helium was used as carrier gas, 2 ml/min) with a Zebron ZB-AAA
capillary column (15 m, 0.25 mm inner diameter, Phenomenex1)
and analyzed using a DSQII mass spectrometer (Thermo Scientiﬁc).
For NICI–GC–MS the injector temperature was set to 280 8C. The
oven temperature was maintained at 100 8C for 5 min, increased
during the ﬁrst ramping step at a rate of 20 8C/min to 175 8C, and
held at 175 8C for 5 min. In the second ramping step the
temperature was raised at a rate of 15 8C/min to 280 8C and held
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and the ion source temperature was 100 8C. All spectra were
monitored in the NICI mode (methane was used as reagent gas),
either in full scan or using selected ion monitoring (SIM) mode. In
SIM, target compounds were identiﬁed at the molecule-speciﬁc
mass-to-charge ratios 288/290 (2-ClHDA) or 296/298 (2-
Cl[13C8]HDA) and by the characteristic isotope distribution of
chlorine (35Cl/37Cl, 3:1). Quantitation of 2-ClHDA was performed
by peak area comparison with 2-Cl[13C8]HDA.
For EI–GC–MS the injector temperature was set to 230 8C. The
oven temperature was maintained at 100 8C for 3 min, increased
during the ﬁrst ramping step at a rate of 30 8C/min to 280 8C, and
held at 280 8C for 2 min. In the second ramping step the
temperature was raised at a rate of 30 8C/min to 320 8C. The
transfer line was kept at 320 8C and the ion source temperature
was 200 8C. Mass spectra were recorded either in full scan or SIM
mode with an electron ionization energy of 70 eV and an emission
current of 100 mA. In SIM, the diagnostic ions used for four-fold
silylated phloretin were at m/z 547 and m/z 562. Three-fold
silylated resveratrol was detected at m/z 429 and m/z 444.
Quantitation of phloretin was performed by peak area comparison
using resveratrol as internal standard.
2.5. Isolation and characterization of 2-ClHDA-conjugated phloretin
DPPC-liposomes containing phloretin and 2-ClHDA were
prepared as described above. After 16 h samples were extracted
twice with ethyl acetate followed by the Folch procedure.
Subsequently, extracts were separated by TLC on silica 60 plates
and CHCl3/MeOH (8:1, v/v) as mobile phase. Under these
conditions phloretin migrated with an Rf of 0.42 and the reaction
product at an Rf of 0.61. Bands were visualized by spraying plates
with 2% (w/v) FeCl3 in 0.5 M HCl and subsequent heating (90 8C,
3 min). For isolation of 2-ClHDA-conjugated phloretin DPPC-
liposomes (15 mg DPPC, 0.9 mM) containing 1.5 mg phloretin
(0.2 mM) and 1.7 mg 2-ClHDA (0.3 mM) in PBS (pH 7.4) were
gently stirred for 24 h at 37 8C under argon in the dark. Extraction
was performed twice with ethyl acetate followed by the Folch
procedure. Combined organic layers were dried in vacuum and
conjugated phloretin was pre-puriﬁed using a Silica 60 column and
CHCl3/MeOH (8:1, v/v) as eluent, followed by preparative TLC using
CHCl3/MeOH (8:1, v/v) as mobile phase. A second lane (used as
reference) was cut-off the plate and stained with FeCl3 as described
above. Comigrating bands were scraped off, extracted with CHCl3/
MeOH and dried under N2. The fraction of the newly formed main
reaction product (Rf 0.61) was scrapped off, extracted twice from
the TLC sorbent with CHCl3/MeOH (2:1, v/v) and analyzed by
HRMS (see below).
2.6. HPLC analysis
Homogeneity of the isolated fractions was analyzed by
reversed-phase HPLC on a Waters HPLC 2690 Module and a
Waters UV 2487 detector (set at 288 nm). Separation was carried
out on a Kromasil C18 column (150  4.6 mm, Altmann Analytik,
Munich, Germany) at a ﬂow rate of 0.8 ml/min by isocratic elution
using acetonitrile/water (5%, v/v) as mobile phase. Under these
chromatographic conditions baseline separation is achieved
(retention time of phloretin and adduct = 1.9 and 7.7 min,
respectively). Quantitation was performed with external calibra-
tion curves.
2.7. NMR
Adduct formation was performed in DPPC liposomes as
described above. For the complete assignment of proton andcarbon signals, 1D (1H, homodecoupled 1H [22], 13C and DEPT-135)
as well as 2D (COSY, HSQC, HMBC, and INADEQUATE) spectra
were acquired. The INADEQUATE experiment was recorded on a
Bruker Avance III 700 MHz NMR spectrometer using a 5 mm TCI
cryogenically cooled probe. All other spectra were obtained on a
Bruker Avance III 500 MHz NMR spectrometer at 298 K using
DMSO-d6 as the solvent. The spectra were processed and analyzed
using TopSpin 3.1 and MestReNova 8.0. Chemical shifts were
referenced relative to the residual solvent signal.
2.8. Enthalpy calculations
All of the calculations were carried out using the Gaussian
09 package [23]. The B3LYP density-functional method [24] in
conjunction with the 6-311G(d,p) basis set was selected for all the
geometry optimizations and frequency analysis. The geometries
were optimized including solvation effects. For this purpose, the
SMD solvation method [25] was employed using water as a
solvent. Frequency calculations at 298.15 K on all the stationary
points were carried out at the same level of theory as the geometry
optimizations to ascertain the nature of the stationary points.
Ground and transition states were characterized by none and
one imaginary frequency, respectively. All of the presented
relative energies are free energies at 298.15 K. To simplify the
calculations a model of the reactants with R and R0 = CH3 was used
(see Fig. 3).
2.9. High-resolution mass spectrometry (HRMS)
Adduct formation was performed in DPPC liposomes as
described above. Matrix-assisted laser desorption ionization-time
of ﬂight (MALDI-TOF) mass spectrometry was performed on a
Micromass TofSpec 2E time-of-ﬂight mass spectrometer. Ions were
generated by irradiation just above the threshold laser power
(laser: wavelength 337 nm, operated at a frequency of 5 Hz).
Positive ion spectra were recorded in reﬂectron mode applying an
accelerating voltage of 20 kV and externally calibrated with a
suitable mixture of polyethyleneglycols. The spectra of 100–150
shots were averaged. Analysis of data was done with MassLynx-
Software V4.1 (Micromass/Waters, Manchester, UK). Samples were
prepared by mixing a solution of dithranol (10 mg/ml in THF), a
solution of the analyte (obtained from TLC as described above), and
a solution of F3CCOONa (NaTFA; 0.1 mg/ml in THF) in the cap of a
microtube in a ratio of 10:2:1 (v/v/v). Samples (0.5 ml) were
deposited on the plate (stainless steel) and allowed to dry under air.
High-resolution EI mass spectra (70 eV, source temperature
250 8C) were recorded on an orthogonal TOF spectrometer (Waters
GCT Premier) equipped with a direct insertion (DI) probe. 0.5 ml of
a solution of the sample that was obtained from TLC were placed in
the glass cup used for DI, dried under atmospheric pressure, and
transferred into the vacuum. The acquisition of mass spectra (mass
range: 50–800 Da; 1 spectrum/s; resolution: approx. 7500 FWHM)
was started immediately. Spectra were continuously acquired
while the sample was heated from RT to 400 8C (heating rate:
40 8C/min). Data were processed using MassLynx (version 4.1).
2.10. Isolation and culture of primary porcine BMVEC
BMVEC from porcine brains were isolated by a combination of
mechanical disintegration, enzymatic digestion, and centrifuga-
tion steps and were cultured exactly as described [10].
For cell culture experiments 2-ClHDA, phloretin, and the
2-ClHDA-phloretin adduct were prepared as stock solutions in
DMSO. Final DMSO concentrations in culture medium were 0.2%
(v/v; impedance measurements) or 0.4% (v/v; MTT test and adduct
formation in BMVEC cultures).
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To investigate the effects of 2-ClHDA-conjugated phloretin on
metabolic activity the MTT test was used [19]. Brieﬂy, BMVEC
were grown in 96-well plates to conﬂuence, serum starved over
night, and treated with 2-ClHDA, phloretin, or the 2-ClHDA-
phloretin adduct in serum-free medium at the indicated
concentrations for 5 h. After treatment, the medium was
replaced by serum-free medium (100 ml per well) containing
MTT (1.2 mM) and the cells were incubated for 1 h under standard
conditions. The cells were washed (PBS) and lysed (isopropanol/
1 M HCl, 24:1 (v/v); 100 ml/well) on a rotary shaker (1000 rpm,
15 min). Absorbance was measured at 570 nm on a Victor
multilabel reader (Wallac) and corrected for background absorp-
tion (650 nm).
2.12. Adenine nucleotide analysis
BMVEC were cultured to conﬂuence in 6-well plates and
serum-starved for 24 h before phloretin, 2-ClHDA, phloretin plus
2-ClHDA, or the 2-ClHDA-phloretin adduct (25 mM each) was
added in serum-free medium. After 8 h the cells were washed,
trypsinized and cellular proteins were precipitated with 0.4 M
perchloric acid. After centrifugation (12,000  g), 100ml of the
supernatant were neutralized with 20–25 ml of potassium
carbonate (2 M, 4 8C). The supernatant (40 ml) obtained after
centrifugation was used for HPLC analysis as described [26]. The
pellets of the acidic extract were dissolved in 50 ml of NaOH (0.1M)
and used for protein determination at a dilution of 1:10 (BCA
Assay; Pierce).
2.13. Electric cell-substrate impedance sensing (ECIS)
BMVEC barrier function was quantitated by impedance
measurement at 4 kHz on collagen-coated gold electrodes of
8W10E+ arrays using an ECIS Z System (Applied Biophysics, Troy,
NY, USA). After induction of tight junction formation by
hydrocortisone endothelial cells were challenged with 2-ClHDA,
phloretin, or the 2-ClHDA-phloretin adduct.
2.14. Western blot analysis
BMVEC protein lysates obtained from cells that were time-
dependently incubated with 2-ClHDA (15 mM; in the absence or
presence of phloretin, 15 mM) were separated by SDS-PAGE and
electrophoretically transferred to PVDF membranes. Phosphospe-
ciﬁc antibodies (rabbit) against pp44/42 and, pSAPK/JNK1/2 (diluted
1:500; 3% BSA in TBS) were applied by overnight incubation at 4 8C.
Immunoreactive bands were visualized using HRP-conjugated goat
anti-rabbit IgG (1:5000 in 5% (w/v) skim milk powder in TBS, 2 h, RT)
and subsequent ECL Plus development. For normalization, mem-
branes were stripped at 50 8C for 30 min with gentle shaking and
reprobed with primary antibodies against corresponding pan-
proteins (overnight at 4 8C, diluted 1:1000, 5% (w/v) skim milk
powder in TBS). Detection of immunoreactive bands was performed
as mentioned above with HRP-conjugated goat anti-rabbit or goat
anti-mouse secondary antibodies (1:5000 in 5% (w/v) skim milk
powder in TBS, 2 h, RT) using a Bio Rad ChemiDoc MP system.
2.15. Adduct formation in BMVEC cultures
BMVEC were grown in collagen-coated 6-well plates to
conﬂuence and were preincubated in the presence of phloretin
in glucose-containing HBSS buffer (pH = 7) for 60 min at 37 8C
before addition of 2-ClHDA (25 mM, ﬁnal concentration). For
adduct analysis 1 ml of the supernatant was extracted twicewith 2 ml ethyl acetate and processed for HPLC analysis (see
below). For 2-ClHDA analyses 1 ml medium (containing 200 ng
2-Cl[13C8]HDA as internal standard) was extracted twice with 2 ml
hexane/methanol (5:1, v/v). Cells were washed with PBS and
cellular lipids were extracted in the presence of 200 ng 2-
Cl[13C8]HDA using two consecutive extractions (30 min, RT) with
1 ml hexane/isopropanol (3:2, v/v) on a rotary shaker (1000 rpm).
2-ClHDA-conjugated phloretin was quantitated by reversed-phase
HPLC and 2-ClHDA concentrations were quantitated using NICI–
GC–MS after preparation of PFB-oxime derivatives.
2.16. Animals and animal experiments
Male C57BL/6J mice (8–10 weeks, 20–30 g) were obtained from
the ‘Institut fu¨r Versuchstierkunde’ (Himberg, Austria). All animal
experiments were performed in accordance with animal care
ethics approval and guidelines, as per Animal Care Certiﬁcate
BMWF-66.010/0055-II/3b/2011 of the Austrian Federal Ministry of
Science and Research (Vienna). All animals were kept on a 12 h
light/dark cycle with free access to food and water. Mice received a
single i.p. dose of phloretin (0.1 mg/g body weight, 100 mM in
DMSO). After 15, 30, 60, 120, and 240 min mice were anesthetized
with 150 mg/kg pentobarbital (Nembutal) and transcardially
perfused with 25 ml PBS. Subsequently, brains were removed,
weighed, snap-frozen in liquid N2, and stored at 70 8C until
further processing. Frozen brain tissues were homogenized using a
BioPulverizer (BioSpec Products, Bartlesville, USA) and extracted
twice with ethyl acetate in the presence of 1 mg resveratrol
(internal standard), which was followed by a Folch extraction.
Polyphenols were puriﬁed from lipid extracts by solid phase
extraction using silica 60 columns, using CHCl3/MeOH (8:1, v/v) as
eluent. After conversion to TMS-ether derivatives (as described
above) polyphenols were quantiﬁed by EI–GC–MS.
2.17. Statistical analyses
Data are presented as means  SD. To test differences in groups,
statistical signiﬁcance was determined by one-way ANOVA with
Bonferroni correction (using the GraphPad 5.0 Prism package) as
indicated. All values of p  0.05 were considered signiﬁcant. *
p < 0.05, ** p < 0.01, *** p < 0.001; * compared to vehicle; # compared
to the same concentration of 2-ClHDA.
3. Results
3.1. Time-dependent scavenging of 2-ClHDA by phloretin
To monitor the rate of 2-ClHDA scavenging by phloretin
(structure shown in Fig. 1A) the reactants were incorporated in
DPPC liposomes at equimolar ratios. At the indicated times
aliquots of the reaction mixture were removed, extracted,
derivatized, and analyzed by NICI–GC–MS. These analyses revealed
that 2-ClHDA concentrations decreased time-dependently (Fig. 1B)
which could be ﬁtted according to a ﬁrst order decay (Ct = Co  ekt;
r2 = 0.98). Of note, the constants reported here are observed rate
constants, not second order rate constants. Under the experimental
conditions used the half-life (t/2) of 2-ClHDA was 120 min, with a
calculated decay rate of 5.9  103 min1. At the latest time point
(24 h) virtually all 2-ClHDA was consumed.
Taking into consideration that both compounds are lipophilic
and could accumulate in hydrophobic compartments (logP values:
phloretin > 2, Ref. [27]; 2-ClHDA = 6.2, ChemDraw calculation) of
biological systems we have analyzed adduct formation in
acetonitrile or THF (both solvents containing 1% triethylamine).
While adduct formation in THF was only observed at 50 8C
(data not shown), time-dependent loss of phloretin in acetonitrile
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Fig. 1. Analyte recovery during 2-ClHDA-phloretin adduct formation. (A) Phloretin structure. The A- and B-ring is indicated. (B) DPPC liposomes containing 2-ClHDA and
phloretin were incubated at 37 8C in PBS. (C) 2-ClHDA and phloretin were incubated in acetonitrile (containing 0.1% triethylamine) at 37 8C. (D) 2-ClHDA and phloretin were
incubated in PBS containing 250 mg HDL protein/ml at 37 8C. At the indicated time points aliquots of the reaction mixture were extracted, and either converted to the
corresponding PFB-oxime derivatives and analyzed by NICI–GC–MS using 2-Cl[13C8]HDA as internal standard (B) or were quantitated by HPLC analysis (C and D) using
external calibration. Results are presented as percentage recovery of the corresponding analytes. Results represent mean  SD from triplicate experiments.
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comparable to what was observed in liposome preparations.
During these experiments adduct accumulation did not match loss
of phloretin (Fig. 1C). Formation of a disubstituted phloretin adduct
in analogy to what was reported for acrolein scavenging by
phloretin [18] could provide a possible explanation for this
observation. This issue was, however, not further addressed
experimentally during the present study. Since BMVEC actively
secrete lipoproteins of the high-density range [28] we have
evaluated whether HDL could provide a hydrophobic environment
that facilitates 2-ClHDA-phloretin adduct formation. These experi-
ments revealed a decay rate for phloretin of 1.4  102 min1 and a
t/2 of 51 min (Fig. 1D) indicating most efﬁcient adduct formation
under these conditions.
3.2. NMR structure elucidation
Hypothetically adduct formation between 2-ClHDA and phlor-
etin could occur via electrophilic aromatic substitution followed by
hemiacetal formation on the A-ring. To characterize the structure
of the 2-ClHDA-phloretin adduct, NMR analyses and theoretical
enthalpy calculations were performed. The isolated product was
dissolved in DMSO-d6 and could be completely assigned using a
combination of 1D (1H, homodecoupled 1H, 13C, DEPT-135) and 2D
(COSY, HSQC, HMBC, INADEQUATE) spectra. Both the HMBC and
INADEQUATE spectra were necessary to unambiguously identify
the adduct structure. An overlay of the HSQC and HMBC spectra,
conﬁrming hemiacetal formation is shown in Fig.2. In particular,
correlations between H-200 with C-7a00, H-300 with C-3a00, and H-200
with C-3a00 in the HMBC, as well as C-300 with C-3a00 and C-3a00
with C-7a00 in the INADEQUATE were important for structureelucidation. The complete assignment is presented in Table 1. This
analysis clearly suggests hemiacetal formation between the
aldehyde and the A-ring of phloretin corresponding to the
structure shown in Fig.2B.
3.3. Enthalpy calculations
To further support these ﬁndings we have performed theoreti-
cal enthalpy calculations. These calculations imply that the
formation of the 2-ClHDA-phloretin adduct is a two-step process
which consists of an electrophilic aromatic substitution followed
by a hemiacetal condensation on the A-ring of phloretin (Fig. 3A).
To conﬁrm this hypothesis and discard an alternative pathway
where the formation of the hemiacetal occurs prior to dechlorina-
tion we performed a computational analysis of the reaction
mechanism using density-functional theory calculations. In a
slightly basic aqueous medium phloretin is dissociated and thus
activated for electrophilic aromatic substitution (Fig. 3B). The
theoretical energy barrier for the initial step is +24.4 kcal/mol,
which is compatible with a process taking place after several hours
at 37 8C. The ensuing open-intermediate rapidly evolves to the
ﬁnal 2-ClHDA-phloretin adduct through the formation of the
hemiacetal moiety. The overall process is exothermic and
27.3 kcal/mol are released during adduct formation (Fig. 3C;
Pathway A). The alternative pathway (Fig. 3D; Pathway B) where
hemiacetal formation starts prior to chlorine abstraction repre-
sents a higher energy barrier (+43.1 kcal/mol) and is, therefore, less
likely to occur. The optimized geometry of the key transition states
involved in adduct formation via both pathways is displayed as
ball-and-stick models in Fig. 3C and D, respectively. The calculated
(ChemDraw) logP value of this adduct is 7.3.
Fig. 2. NMR analysis of the 2-ClHDA-phloretin adduct. (A) Overlay of the HSQC
(blue) and HMBC (red) spectra of the 2-ClHDA-phloretin adduct. Key connectivities
are indicated. (B) Adduct structure, name, and numbering scheme as applied in A
and Table 1.
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After reaction in liposomes, the adduct was isolated by TLC as
described in the Methods section. One new major band (Rf = 0.61)
was well separated from the original reactants. This band was
scrapped off, extracted with CHCl3/MeOH (8:1, v/v), and subjected
to HRMS analysis. The important part of the MALDI-TOF mass
spectrum is shown in Fig. 4A. Three signiﬁcant peaks were detected
at m/z 513.3, 535.3, and 557.3 Da. These peaks are assigned to ions
[MH]+, [MNa]+, and [(M  H + Na)Na]+, respectively, where MTable 1
NMR data of the adduct corresponding to 3-(4-hydroxyphenyl)-1-(2,4,6-trihy-
droxy-3-tetradecyl-2,3-dihydrobenzofuran-7-yl)propan-1-one acquired in DMSO-
d6. Numbering and structure is shown in Fig. 2B.
Position d(1H) [ppm] Multiplicity d(13C) [ppm]
1 – – 202.9
2 2.78 t 29.6
3 3.18 t 44.9
10 – - 131.5
20 , 60 7.03 d 129.4
30 , 50 6.66 d 115.2
40 9.18 s 155.5
200 5.73 d 107.8
200 (OH) 7.53 d –
300 2.94 d 46.7
3a00 – - 107.1
400 10.66 s 160.9
500 5.84 s 95.6
600 13.17 s 164.8
700 – – 100.6
7a00 – – 161.1
i 1.68 m 31.7
ii–xii 1.25 m 31.2
xiii 1.25 m 22.4
xiv 0.83 t 14.3corresponds to the adduct shown in Fig. 2B (C31H44O6, mono-
isotopic mass 512.3 Da). [MNa]+ was observed as the base peak.
This is in agreement with the experimental conditions used for the
sample preparation (matrix system: dithranol/NaTFA). The insets
in Fig. 4A,a and b show a comparison of measured and calculated
accurate masses. The experimental result of m/zexp = 535.3016 Da
closely corresponds to the calculated mass of the monoisotopic
peak of [MNa]+ (C31H44O6Na, m/zcalc = 535.3036 Da). Thus, the
MALDI-TOF mass spectrum conﬁrms the results obtained by NMR.
DI-EI analysis generated the mass spectrum shown in Fig. 4B. The
peak observed at m/z = 512.3157 Da (Fig.4B,b) is interpreted
as the monoisotopic peak of molecular ion [M]+ (C31H44O6:
m/zcalc = 512.3138 Da, compare inset of Fig.4B,a), in line with
the structure shown in Fig.2B. Various other fragment ions
observed in the EI spectrum correspond to the anticipated
structure, e.g. m/z = 494.3053 Da can be assigned to [M  H2O]+
(C31H42O5, m/zcalc = 494.3032 Da) and the signal at m/z = 107.0 Da
corresponds to [CH2PhOH]
+ (C7H7O, m/zcalc = 107.0 Da).
3.5. Adduct formation preserves BMVEC function
Next we investigated the impact of 2-ClHDA, phloretin, and the
2-ClHDA-phloretin adduct on metabolic activity of BMVEC. As
expected and addressed earlier [19], MTT reduction was signiﬁ-
cantly attenuated by 2-ClHDA (Fig. 5A; 60% reduction at 50 mM)
indicating signiﬁcantly reduced cellular metabolic activity. The
presence of phloretin tended to increase MTT reduction. Of note,
the isolated 2-ClHDA-phloretin adduct had no effect on MTT
reduction at 15 and 25 mM while a slight (14%) decrease was
observed at 50 mM.
Comparable observations were made for the intracellular
adenine nucleotide status: 2-ClHDA signiﬁcantly reduced cellular
ATP concentrations (from 52.2 to 32.2 nmol/mg protein vehicle vs.
2-ClHDA); this effect was almost completely attenuated in the
presence of 2-ClHDA plus phloretin (51.1 nmol/mg protein) and
the 2-ClHDA-phloretin adduct (47.5 nmol/mg protein; Fig. 5B).
AMP levels were increased by 4.4-fold in 2-ClHDA-treated cells
(2.2 vs. 0.5 nmol AMP/mg protein, 2-ClHDA vs. vehicle). Of note,
addition of the adduct was without effect on the cellular AMP
content, while in 2-ClHDA plus phloretin-treated cells AMP
concentrations were 2-fold higher when compared to adduct-
treated BMVEC. The differences were less pronounced in terms of
ADP concentrations (6.3 vs. 4.2 nmol/mg protein, 2-ClHDA vs.
vehicle). However, also ADP levels were higher in 2-ClHDA plus
phloretin as compared to adduct-treated cells (5.2 vs. 4.2 nmol/mg
protein). These ﬁndings were also reﬂected in the ATP/ADP ratios
(Fig. 5C), although the difference between 2-ClHDA plus phloretin
and adduct-treated cells did not reach statistical signiﬁcance
(p = 0.0619). Phloretin alone slightly increased the ATP/ADP ratio.
As reported earlier [10] and observed here, 2-ClHDA induces
severe loss of BMVEC barrier function as revealed by ECIS
measurements (Fig. 5D). In contrast, the covalent 2-ClHDA-
phloretin adduct was almost without effect on barrier function.
Statistical evaluation of the relative impedance data at 4 h is shown
in Fig. 5E. These ﬁndings indicate that phloretin efﬁciently reduces
deleterious effects of 2-ClHDA on metabolic and barrier function of
BMVEC.
MAPK signaling plays a critical role in the regulation of barrier
integrity [29,30]. In line, our earlier studies demonstrated that
pharmacological antagonism of p44/42 and SAPK/JNK1/2 activa-
tion prevented 2-ClHDA-mediated BMVEC barrier dysfunction [19].
To investigate whether phloretin could interact with these events
cells were incubated with 2-ClHDA in the absence or presence of
phloretin. These experiments corroborated that phloretin led to
substantially reduced activation of p44/42 and SAPK/JNK1/2 by
2-ClHDA (Fig. 5F).
Fig. 3. Theoretical enthalpy calculations based on NMR data. (A) Overall energy proﬁle for the formation of the 2-ClHDA-phloretin adduct via electrophilic aromatic
substitution followed by hemiacetal formation (Pathway A; 1 = 2-ClHDA, 2 = phloretin (for structure see Fig. 1A), 3 = adduct (for complete structure see Fig. 2B). To simplify
enthalpy calculations R and R0 = CH3. (B) Under slightly basic conditions the A-ring of phloretin (2) is dissociated (20 and 200) and thus activated for electrophilic aromatic
substitution. 200 is more stable than 20 (11.3 kcal/mole). (C) Energy proﬁle (upper panel) for the formation of the 2-ClHDA-phloretin adduct via electrophilic aromatic
substitution followed by hemiacetal formation (Pathway A). Relative free energy (in kcal/mol) with respect to 1 and 200 are calculated at the B3LYP/6-311G(d,p) level. The
ball and stick model (lower panel) shows optimized geometry of the key transition states involved in the formation of the 2-ClHDA-phloretin adduct via Pathway A
(calculated distances are given in A˚). (D) Energy proﬁle (upper panel) for the formation of the 2-ClHDA-phloretin adduct via hemiacetal formation and subsequent
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Fig. 4. HRMS analysis of the product obtained by reaction of 2-ClHDA with phloretin. (A) MALDI-TOF mass spectrum of the 2-ClHDA-phloretin adduct. The insets display
the calculated isotope pattern of [C31H44O6Na]
+ (a), and the accurate mass data obtained experimentally (b). (B) Direct inlet-EI mass spectrum of the 2-ClHDA-phloretin
adduct. The insets display the calculated isotope pattern of [C31H44O6]
+ (a), and the accurate mass data obtained experimentally (b).
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adduct formation, 2-ClHDA and phloretin were added to the
supernatant of conﬂuent BMVEC monolayers. Since 2-ClHDA may
be converted to the corresponding acid and alcohol under these
conditions [19], we have chosen short incubation times to (at least
partially) overcome this limitation. Data from these experiments
(Table 2) indicate that 19 (15 min) and 14% (60 min) of 2-ClHDA
are recovered as adduct from the cellular supernatant. Approx. 5%
of 2-ClHDA were recovered as cell-associated adduct (Table 2).
3.6. In vivo brain uptake of phloretin
To get an indication whether peripherally administered phloretin
is able to cross the BBB in vivo C57BL/6J mice were injected i.p. with
phloretin. At the time points indicated animals were anesthetized
and transcardially perfused. Brains were removed, weighed,
homogenized, extracted, and the corresponding phloretin TMS-
ether derivatives were quantitated by EI–GC–MS. Fig.6A,a shows
SIM traces of TMS-ether derivatives of phloretin (analyzed from
brain lipid extracts prepared 15 min post i.p. injection; diagnosticelectrophilic aromatic substitution (Pathway B). Relative free energy with respect to 1 an
model (lower panel) shows optimized geometry of the key transition state involved in t
are given in A˚).ion at m/z = 547, resulting from M+ CH3) and resveratrol
(diagnostic ion at m/z = 444; [M+]) which was used as internal
standard. As is evident from the SIM trace, trans-resveratrol and
phloretin co-eluted, while cis-resveratrol was separated from
phloretin (retention time = 7.86 min; Fig.6A,b). Fragment ion
intensity (and mass assignment for the major fragments) ratios of
phloretin and the internal standard are shown in Fig. 6A,c. Time-
dependent accumulation of phloretin in mouse brain is shown in
Fig. 6B. These experiments revealed maximum phloretin concen-
trations 15 min post application (1.2 mg/g brain tissue; based on the
average mouse brain weight of 400 mg this corresponds to approx.
0.015% of totally administered phloretin). In brain of control animals
phloretin was undetectable. These data indicate that phloretin is
subject to transport across the murine BBB in vivo.
4. Discussion
Here we describe a phloretin-mediated detoxiﬁcation pathway
for a chlorinated fatty aldehyde that has detrimental effects on BBB
function in vitro and in vivo. Members of the polyphenol familyd 200 (in kcal/mol) are calculated at the B3LYP/6-311G(d,p) level. The ball and stick
he formation of the 2-ClHDA-phloretin adduct via Pathway B (calculated distances
Fig. 5. Phloretin ameliorates cytotoxic properties of 2-ClHDA on brain endothelial cells. (A) Results for MTT reduction in the presence of the indicated compounds are
expressed as % of vehicle control (‘V’; DMSO, 0.4%) and represent mean  SD from seven independent determinations. *** p < 0.001 vs. vehicle treatment; ### p < 0.001 vs. equal
2-ClHDA concentrations; one-way ANOVA and Bonferroni comparison). (B) Cellular adenine nucleotide levels (ATP, ADP, and AMP) were analyzed in the presence of the indicated
compounds (25 mM) by HPLC. Vc = vehicle control. Results represent mean  SD from six dishes. *** p < 0.001 vs. vehicle treatment, one-way ANOVA and Bonferroni comparison.
(C) ATP/ADP ratios in the presence of the indicated compounds (25 mM). *** p < 0.001 vs. vehicle treatment, one-way ANOVA and Bonferroni comparison; n.s. = not signiﬁcant. (D)
BMVEC were plated on gold microelectrodes and cultured to conﬂuence. Impedance of hydrocortisone-induced monolayers (7.5  104 cells) was continuously monitored at 4 kHz.
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Table 2
2-ClHDA-phloretin adduct formation in BMVEC cultures. Conﬂuent BMVEC
monolayers were preincubated in glucose-containing HBSS (2 ml) in the presence
of phloretin for 60 min. After addition of 2-ClHDA (25 mM) the cellular supernatant
and cell monolayers were extracted after 15 and 60 min and analyzed either by
HPLC–UV detection (2-ClHDA-conjugated phloretin) or by NICI–GC–MS (2-ClHDA).
Time (min) Supernatanta Cell-associateda Totalb
2-ClHDA Adduct 2-ClHDA Adduct
15 74  9.7c 19  3.4 14  4.6 5  0.8 112
60 41  11.9 14  2.6 24  1.6 4  0.3 83
a Results are given as % of added 2-ClHDA (25 mM).
b Sum of analytes recovered from the medium and in cell association.
c Results shown represent mean  SD (n = 3).
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neurodegenerative conditions [31–33] that are invariably accom-
panied by different stages of oxidative stress [34]. Polyphenols are
able to inhibit the formation of reactive species [35], reduce
transition metal availability [36], and covalently bind reactive
unsaturated aldehydes [37]. Systemic inﬂammation results in
immune cell recruitment to the cerebrovasculature where
neutrophils release MPO to generate MPO-derived oxidants [10].
During the present study we investigated the potential of
phloretin, a dihydrochalcone, to act as a sink for the reactive
chlorinated aldehyde 2-ClHDA. 2-ClHDA has potent signaling
[11,38,39] and pro-apoptotic properties [10,19] and mimics some
of the detrimental effects that are linked to plasmalogen deﬁciency
in brains of Alzheimer’s disease patients [40]. As reported here,
adduct formation with phloretin occurs at ambient conditions via
electrophilic aromatic substitution and subsequent cyclic hemiac-
etal formation. This process ameliorates most of the harmful
effects of 2-ClHDA on brain endothelial cell function.
Initially we have determined adduct formation under different
conditions (Fig.1). These experiments revealed most efﬁcient
adduct formation in the presence of HDL particles. These ﬁndings
could indicate that HDL (which is actively secreted by BMVEC; Ref.
[28]) could provide a hydrophobic environment facilitating 2-
ClHDA-phloretin interaction. Adduct formation is a relatively slow
process with observed rate constants between 1.4  102 to
4.4  103 min1 (Fig.1). Nevertheless, phloretin (added in the
presence of 2-ClHDA) provided protection against ATP depletion
(Fig.5B) and rescued barrier dysfunction [19] at 2-ClHDA
concentrations comparable to what was reported for in vivo
systems (1–20 mM; Refs. [9,41,42]). These observations could be
due to the fact that adduct formation reduces 2-ClHDA concentra-
tions to a sub-lethal range or suppresses early electrophile-
mediated signaling events (i.e. p44/42 and SAPK/JNK1/2 activa-
tion; Fig.5F) that are able to induce cell damage in a hierarchical
manner. Our ongoing studies indicate that 2-ClHDA is able to
covalently modify BMVEC proteins (C.N., N.K., E.M., and W.S.;
unpublished). Adduct formation with phloretin would thus reduce
the concentration of 2-ClHDA that is available to inﬂict alkylation
damage (as reported for 4-hydroxynonenal, another reactive
aldehyde formed in vivo; Ref. [43]) to cellular proteins.
NMR, enthalpy calculation, and HRMS (Figs.2–4) suggest that
adduct formation between 2-ClHDA and phloretin at ambient
conditions (37 8C, pH 7.4) proceeds via aromatic electrophilic
substitution followed by hemiacetal formation at the A-ring of
phloretin, while the B-ring is apparently not involved. Formation of
the transition complex starts with electrophilic attack of 2-ClHDAAfter monolayer stabilization, cells were incubated with vehicle (DMSO, 0.2%; ‘1’), phloretin
Impedance was monitored over 4 h. The arrow indicates addition of compounds. (E). Statisti
were normalized to treatment start and represent mean values  SD of four independent e
ANOVA and Bonferroni comparison). (F) BMVEC were incubated with 2-ClHDA (15 mM) or 2
subjected to SDS-PAGE and transferred to PVDF membranes. Pan- or phospho-speciﬁc pol
Immunoreactive bands were visualized with HRP-conjugated secondary antibodies using at C-5 of the A-ring. Subsequently, nucleophilic attack at the
terminal aldehyde by a nearby hydroxyl group at C-6 leads to the
formation of a cyclic hemiacetal as the stable end product.
Whether metal catalysis contributes to adduct formation was
experimentally not addressed during the present study. There is
ample evidence that phloretin can interact at several stages of
‘oxidative stress’: Phloretin acts as antioxidant by scavenging
radical species [44], inhibits the formation of lipid hydroperoxides
[45], and covalently traps a,b-unsaturated aldehydes [37]. Zhu
and colleagues [18] have reported that among several different
polyphenol classes only ﬂavan-3-ols, theaﬂavins, cyanomaclurins,
and dihydrochalcones (all containing a phloroglucinol moiety, the
A-ring of phloretin) are able to trap reactive carbonyl species.
Among the active compounds, phloretin most efﬁciently binds
acrolein and 4-hydroxynonenal. LC–MS and NMR analyses
revealed that both, 4-hydroxynonenal and acrolein are subject
to aromatic electrophilic substitution at the A-ring of phloretin
followed by hemiacetal formation in aqueous solution [18]. Of
note, acrolein can be generated by MPO-mediated oxidation of
threonine and subsequent water abstraction of the 2-hydroxy-
propanal intermediate [46]. Involvement of the A-ring of phloretin
was also demonstrated to be involved in scavenging of acetalde-
hyde and glyoxylic acid [47] as well as glyoxal and methylglyoxal
[48]. Thus the reaction mechanism identiﬁed here for a chlorinated
fatty aldehyde (Fig.3) is in line with reports for other reactive
carbonyl species. In terms of pharmacological applicability it
should be noted that phloretin inhibits glucose uptake into brain
and brain endothelial cells in vitro [49] and in vivo [50,51].
As noted above, the pharmacophore facilitating covalent
trapping of reactive carbonyl species is the phloroglucinol moiety.
Based on this structural element, LoPachin and colleagues [52]
have demonstrated that simple b-dicarbonyl enolates like e.g.
acetylacetone, 1,3-cyclopentandione, or 2-acetylcyclopentanone
are able to provide neuroprotection from aldehyde-induced
toxicity and thiol loss in vitro. The same group [53] reported that
2-acetylcyclopentanone protects against acetaminophen-mediat-
ed hepatotoxicity in vivo.
To fulﬁll a neuromodulatory role, polyphenols have to cross the
BBB. Flavonoid uptake has been correlated with increased
cognitive performance in experimental animal models, suggesting
a neuroprotective role of these compounds [31,32]. Under our
experimental conditions approx. 0.015% of phloretin (applied i.p.)
was recovered in the brain lipid fraction of C57BL/6J mice (Fig.6B)
indicating penetration of the murine BBB. This might result from
the fact that the logP of phloretin is >2 [27] since BBB penetration
is optimal when the logP values are in the range of 1.5-2.7 [54]. In
line, naringenin, a compound structurally related to phloretin
(logP = 1.9; Ref. [55]) was shown to cross the BBB in vitro and in
vivo [56]. Findings of the present study indicate that concentra-
tions of phloretin (15 min post administration) in murine brain are
approx. 6 mM (dropping to 2.2 mM at 240 min). This is in the range
of cerebral concentrations of the neuroprotective antioxidant a-
tocopherol (4 mM; Ref. [57]). Hypothetically these phloretin
concentrations would sufﬁce to scavenge the peak levels of 2-
ClHDA that is generated under neuroinﬂammatory conditions in
the murine brain (Cmax  10 mM; Ref. [9]). However, in light of the
rate constants determined for adduct formation (5.9  103 and
1.4  102 min1, liposomes and HDL, respectively) the ability of
phloretin to scavenge 2-ClHDA efﬁciently under in vivo conditions
remains to be demonstrated. (15 mM; ‘2’), 2-ClHDA (15 mM; ‘3’), or puriﬁed 2-ClHDA-phloretin adduct (15 mM; ‘4’).
cal evaluation of relative impedance values (1–4) after 4 h from (D). Impedance values
xperiments (*** p < 0.001 vs. vehicle treatment; ### p < 0.001 vs. 2-ClHDA; one-way
-ClHDA plus phloretin (15 mM each). Aliquots of cell lysates (50 mg protein/lane) were
yclonal antibodies against p44/42 or SAPK1/JNK1/2 were used as primary antibodies.
the Bio Rad ChemiDoc system.
Fig. 6. Phloretin accumulation in murine brain after i.p. administration. C57BL/6J mice (n = 3/group) received a single injection (i.p.) of phloretin (0.1 mg/g body weight).
At the indicated times brains were removed, homogenized, extracted, and phloretin was analyzed by EI–GC–MS analysis in the SIM mode and quantitated using resveratrol as
internal standard. (A) SIM trace of a representative brain lipid sample (15 min post phloretin application) containing resveratrol as internal standard. Phloretin (a) was
monitored at m/z 562 [M+] and 547 [M+  CH3], resveratrol (b) was monitored at m/z 444.3 [M+]. Note coelution of trans-resveratrol with phloretin. Fragment ion intensity
ratios of phloretin and the internal standard are shown in (c). Mass assignment for the major fragments is indicated. (B) Time-dependent quantitation of phloretin in mouse
brain homogenates after i.p. application. Results shown represent mean  SD from three animals per time point.
A. U¨llen et al. / Biochemical Pharmacology 93 (2015) 470–481480In conclusion, we have characterized the reaction mechanisms
governing covalent adduct formation between phloretin and
2-ClHDA, a process ameliorating detrimental effects of this
chlorinated fatty aldehyde on brain endothelial cell function.
Whether these ﬁndings can be translated into therapeutic
applications to improve the outcome of neuroinﬂammatory
conditions remains to be elucidated.
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